Who is the CEO of 3billion?

According to the DART company overview, 3billion's representative director is 금창원 (name as registered in Korean). The company was founded on 2016-10-10.

Where is 3billion listed?

3billion trades on the Korea Exchange KOSDAQ market under the ticker 394800. Its fiscal year ends in December.

Does 3billion pay a dividend?

3billion did not pay a cash dividend for fiscal 2025, according to its annual report.

Does 3billion have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: 4 quarters of losses (operating loss in each of the last four quarters). These are factual flags, not investment advice.

Which companies are in the same industry as 3billion?

Under the Korean Standard Industrial Classification recorded on DART, 3billion is grouped with 77 other listed companies in research & development. The most covered in Korean news over the past 30 days are SK biopharmaceuticals, Alteogen and D&D Pharmatech.

3billion KRX:394800KOSDAQ

쓰리빌리언 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days13

DART filings, 7 days1

Articles tracked80since Sep 11

In Q3 2026, 3billion reported revenue of ₩4.2bn, up 30.0% year on year, and an operating loss of ₩1.2bn. 3billion (쓰리빌리언) appeared in 13 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Nov 13 with 9 articles. The most common catalyst was earnings (4). It was most often mentioned alongside 글로벌테크놀로지, JLK and Seers.

Filing signals 4 quarters of losses Screener

3billion quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q3 2026	₩4.2bn	+30.0%	−₩1.2bn margin −29.4%	−₩2.7bn
Q2 2026	₩3.8bn	+46.4%	−₩1.7bn margin −43.9%	₩6.7bn
Q1 2026	₩3.4bn	+67.8%	−₩1.7bn margin −49.4%	−₩1.5bn
Q3 2025	₩3.2bn	+102.5%	−₩1.3bn margin −39.3%	−₩1.1bn
Q2 2025	₩2.6bn	+100.9%	−₩1.6bn margin −61.5%	−₩1.6bn
Q1 2025	₩2.0bn	+115.6%	−₩2.0bn margin −98.1%	−₩1.7bn
Q3 2024	₩1.6bn	–	−₩1.7bn margin −105.7%	−₩1.5bn
Q2 2024	₩1.3bn	–	−₩1.6bn margin −124.4%	−₩1.7bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

3billion top stories 2 weeks, by number of outlets

1
3 Billion achieves 11.4 billion won cumulative 3Q sales
3 outlets · 3 articlesFirst report Nov 13 14:29 뉴스핌
2
Threebillion third quarter cumulative revenue 11.4 billion, increases R&D and reduces deficit
2 outlets · 2 articlesFirst report Nov 13 14:53 이데일리
3
Three Billion reveals AI new drug development technology at Bio Europe 2026
2 outlets · 2 articlesFirst report Nov 3 08:42 뉴스핌
4
3BILLION unveils AI new drug development strategy using patient genomic data in Europe
2 outlets · 2 articlesFirst report Nov 3 09:37 알파경제
5
Three Billion jointly develops AI new drug with France's DeepLife...pursues global technology transfer
1 outlets · 1 articlesFirst report Nov 10 15:16 전자신문Licensing deal글로벌테크놀로지
6
Three Billion Q3 cumulative revenue up 45%...rare disease diagnosis business growth
1 outlets · 1 articlesFirst report Nov 13 15:27 서울경제Earnings

Latest 3billion news Korean headlines

Nov 1315:41

MajorAI healthcare: CoreLine Software Q3 cumulative consolidated revenue 5.22 billion won...up 76.4% year-on-year, others including Three Billion and JLK
글로벌경제신문EarningsJLK Coreline Soft
Nov 1315:27

MajorThree Billion Q3 cumulative revenue up 45%...rare disease diagnosis business growth
서울경제Earnings
Nov 1314:53
Threebillion third quarter cumulative revenue 11.4 billion, increases R&D and reduces deficit
이데일리
1 more on this story · 1 outlets
- Three Billion posts 11.4 billion won cumulative Q3 revenue...up 45.1% year-on-year라포르시안 · Nov 13 15:29
Nov 1314:39

Three Billion posts 1.2 billion won operating loss in 3Q…shrinks 26% from previous quarter
뉴스1
Nov 1314:35

3 Billion achieves year's sales in just 3 quarters with 11.4 billion won cumulative revenue
뉴시스경제
Nov 1314:29
3 Billion achieves 11.4 billion won cumulative 3Q sales
뉴스핌
2 more on this story · 2 outlets
- Three Billion cumulative Q3 sales 11.4 billion won...up 45.1% year-on-year이투데이 · Nov 13 16:36
- Three Billion reports accumulated Q3 sales of 11.4 billion won on overseas genetic diagnostics growth, operating loss ratio improves전자신문 · Nov 13 16:46
Nov 1207:01

Lunit, Ceres, ThreeBillion, Coreline: Each charting its own course for global expansion
청년의사Overseas expansionLunit Seers 글로벌테크놀로지
Nov 1109:26

MK Golden Cross breakout candidates: Korea Tire and Technology (161390) and ThreeBillion (394800)
매일경제Hankook Tire & Technology
Nov 1016:27

GC Media I 3Q cumulative consolidated sales 154.1 billion won…profitability accelerating plus Three Billion and JLK
글로벌경제신문GC MediAI JLK
Nov 1015:16

MajorThree Billion jointly develops AI new drug with France's DeepLife...pursues global technology transfer
전자신문Licensing deal글로벌테크놀로지
Nov 310:38

Three Billion unveils AI drug development strategy at BioEurope 2026
라포르시안
Nov 310:11

Three Billion's AI drug development competitiveness showcased at BioEurope among others Noeul and Galaxy
글로벌경제신문
Nov 309:37
3BILLION unveils AI new drug development strategy using patient genomic data in Europe
알파경제
1 more on this story · 1 outlets
- 3BILLION unveils AI new drug development strategy using patient genomic data in Europe메디컬투데이 · Nov 3 09:37
Nov 309:18

ThreeBillion unveils AI new drug strategy at BioEurope
뉴시스경제
Nov 308:42
Three Billion reveals AI new drug development technology at Bio Europe 2026
뉴스핌
1 more on this story · 1 outlets
- Three Billion announces AI new drug development strategy at 'Bio Europe'메디파나뉴스 · Nov 3 08:47
Oct 2721:55

ThreeBillion builds Peru diagnostic testing infrastructure with Koica support, launching AI solution Zebra in Central and South America
벤처스퀘어
Oct 2716:04

AI Healthcare: Three Billion, genetic diagnosis 'Zebra' enters Central and South America market and others
글로벌경제신문JLK
Oct 2710:03

Three Billion introduces AI genetic diagnosis Zebra to Central and South American public healthcare market
라포르시안
Oct 2709:07
Three Billion selected as KOICA partner, to establish rare disease diagnostic system in Peru
파이낸셜뉴스
1 more on this story · 1 outlets
- Three Billion builds Peru genetic diagnostics infrastructure, selected for KOICA project바이오타임즈 · Oct 27 10:54
Oct 2709:04
Three Billion establishes AI genetic diagnosis system in Peru through KOICA project
메디컬투데이
2 more on this story · 2 outlets
- ThreeBillion establishes AI genetic diagnosis system in Peru, targeting Central and South America메디파나뉴스 · Oct 27 09:42
- 3 Billion, building AI genetic diagnosis system in Peru... targeting Central and South American public healthcare market전자신문 · Oct 27 13:46
Oct 2708:59
3Billion selected for KOICA IBS project
뉴스핌
1 more on this story · 1 outlets
- Three Billion eyes Central and South America healthcare...selected for KOICA project뉴시스경제 · Oct 27 09:22
Oct 2615:09

3 Billion rises over 13% during market to 5,690 won
비건뉴스
Oct 2206:37
Big data analysis: Listed health management technology companies October 2026 brand reputation ranking: 1st Lunit, 2nd Cears, 3rd ThreeBillion
일간투데이Lunit Seers
1 more on this story · 1 outlets
- Listed health management technology companies October 2026 brand reputation ranking: Lunit, Cears, ThreeBillion에너지신문 · Oct 22 12:22
Oct 1612:54
ThreeBillion to present 4 rare disease diagnosis research projects at ASHG 2026
바이오타임즈
1 more on this story · 1 outlets
- ThreeBillion to present 4 genomic research projects at ASHG 2026메디포뉴스 · Oct 16 23:14
Oct 1612:01

AI Healthcare: ThreeBillion reduces diagnosis blind spots and improves analysis efficiency, plus Medical AI and JLK
글로벌경제신문JLK
Oct 1610:44
ThreeBillion presents 4 AI genetic diagnosis research projects at human genetics conference
뉴스핌
1 more on this story · 1 outlets
- ThreeBillion presents 4 AI genomic research projects at international human genetics conference전자신문 · Oct 16 14:01
Oct 1609:33
ThreeBillion increases rare disease genetic analysis speed 4 times
파이낸셜뉴스
1 more on this story · 1 outlets
- ThreeBillion increases AI genomic analysis speed 4 times, unveils 4 rare disease diagnosis research projects벤처스퀘어 · Oct 16 19:22
Oct 1609:27

ThreeBillion to present 4 research projects at ASHG 2026, North America's largest human genetics conference
뉴스1
Oct 1116:32

American business newcomer Eric Zmuda: why ThreeBillion chose him
블로터
Oct 715:27

ThreeBillion celebrates 10th anniversary, used in 75 countries
뉴시스경제

Articles per day 2 weeks

210

111

112

913

Company profile

CEO: 금창원
Industry: Research & development
Founded: 2016-10-10
Fiscal year-end: December
Head office: 서울특별시 강남구
Website: 3billion.io
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Major shareholders latest 5%+ report per holder

Korea 5% stake disclosures

금창원23.98%

Each holder's most recent 5% ownership report on DART; names as filed in Korean.

Same industry Research & development

All in industry

Company	Latest quarter op. profit	Articles 30d
SK biopharmaceuticals	–	324
Alteogen	–	256
D&D Pharmatech	−₩13.6bn	72
LigaChem Biosciences	−₩50.4bn	69
Curocell	−₩7.7bn	51
HLB Pharmaceutical	₩847m	44
SillaJen	–	44
Onconic Therapeutics	–	43

Compare 3billion side by side with these companies

3billion DART filings

Nov 1313:27

Quarterly report (September 2026)
Other
Oct 1312:28

Corporate briefing (IR) held
Other
Oct 213:59

Large share holding status report (abbreviated form)
Ownership reports
Oct 113:57

Corporate briefing (IR) held
Other

Catalysts 2 weeks

Earnings4
Policy & overseas1
Contracts & orders1

Mentioned alongside 2 weeks

3billion FAQ

Who is the CEO of 3billion?: According to the DART company overview, 3billion's representative director is 금창원 (name as registered in Korean). The company was founded on 2016-10-10.
Where is 3billion listed?: 3billion trades on the Korea Exchange KOSDAQ market under the ticker 394800. Its fiscal year ends in December.
What were 3billion's latest quarterly results?: In Q3 2026, 3billion reported revenue of ₩4.2bn, up 30.0% year on year, and an operating loss of ₩1.2bn. Figures come from reports filed on DART.
Does 3billion pay a dividend?: 3billion did not pay a cash dividend for fiscal 2025, according to its annual report.
Does 3billion have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: 4 quarters of losses (operating loss in each of the last four quarters). These are factual flags, not investment advice.
Which companies are in the same industry as 3billion?: Under the Korean Standard Industrial Classification recorded on DART, 3billion is grouped with 77 other listed companies in research & development. The most covered in Korean news over the past 30 days are SK biopharmaceuticals, Alteogen and D&D Pharmatech.